Lv43
552 积分 2025-01-07 加入
The fibrinolytic system in disease: From molecular pathways to clinical outcomes
1天前
已完结
Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial
6天前
已完结
The past and future of haemophilia: diagnosis, treatments, and its complications
6天前
已完结
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
6天前
已完结
Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS
26天前
已完结
Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions
1个月前
已完结
Hallmarks of cancer—Then and now, and beyond
1个月前
已完结
Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review
1个月前
已完结
Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?
1个月前
已完结
Molecular mechanisms controlling age‐associated B cells in autoimmunity*
1个月前
已完结
皖公网安备34019202002308
